Current advances and future directions in combined hepatocellular and cholangiocarcinoma  

作　　者：Yu-Zhu Zhang Yu-Chen Liu Tong Su Jiang-Nan Shi Yi Huang Bo Liang 

机构地区：[1]Department of General Surgery,The Second Affiliated Hospital of Nanchang University,Jiangxi,Nanchang,Jiangxi,P.R.China [2]The Second Clinical Medical College of Nanchang University,The Second Affiliated Hospital of Nanchang University,Jiangxi,Nanchang,Jiangxi,P.R.China [3]Queen Mary School,Jiangxi Medical College of Nanchang University,Nanchang,Jiangxi,P.R.China

出　　处：《Gastroenterology Report》2024年第1期514-525,共12页胃肠病学报道(英文)

基　　金：supported by the National Natural Science Foundation of China[82160578];the Natural Science Foundation of Jiangxi Province[20212BCJ23024];the Health Department of Jiangxi Province[202130346].

摘　　要：The low incidence of combined hepatocellular cholangiocarcinoma(cHCC-CCA)is an important factor limiting research progression.Our study extensively included nearly three decades of relevant literature and assembled the most comprehensive database comprising 5,742 patients with cHCC-CCA.We summarized the characteristics,tumor markers,and clinical features of these patients.Additionally,we present the evolution of cHCC-CCA classification and explain the underlying rationale for these classification standards.We reviewed cHCC-CCA diagnostic advances using imaging features,tumor markers,and postoperative pathology,as well as treatment options such as surgical,adjuvant,and immune-targeted therapies.In addition,recent advances in more effective chemotherapeutic regimens and immune-targeted therapies were explored.Furthermore,we described the molecular mutation features and potential specific markers of cHCC-CCA.The prognostic value of Nestin has been proven,and we speculate that Nestin will also play a role in classification and diagnosis.However,further research is needed.Moreover,we believe that the possibility of using machine learning liquid biopsy for preoperative diagnosis and establishing a scoring system are directions for future research.

关 键 词：cHCC-CCA epidemiological features classification molecular mutation characteristics diagnosis treatment 

分 类 号：R73[医药卫生—肿瘤]